Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III/IV Carcinoma of Anus

NCT04046133 is registered in ClinicalTrials.gov with Cardiff University as lead sponsor.

NCT NCT04046133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04046133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III/IV Carcinoma of Anus
Lead sponsor
Cardiff University
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 19, 2020
Completion date
November 30, 2026
Enrollment
52 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer stage iii a, anal cancer stage iii b